BRCA1 and familial pancreatic carcinoma: Results of the phase 3 POLO trial showed that pancreatic cancer patients with BRCA1/2 PGVs receiving PARP inhibitor (PARPi) olaparib had longer progression‐free survival (PFS) than placebo, although there was no difference in overall survival (OS) between the olaparib and placebo groups.7